Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

R. Channick, S. Medrek, M. Delcroix, S. Gaine, P. Jansa, I. Lang, V. McLaughlin, S. Mehta, T. Pulido, B. Sastry, R. Souza, A. Torbicki, C. Zhao, P. Strachan, P. Agron, J. Yen, O. Sitbon

. 2025 ; 7 (-) : 100197. [pub] 20250116

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25008493

BACKGROUND: Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS: Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIPHON; NCT01106014) versus placebo (primary endpoint: time to morbidity/mortality [M/M]). This analysis defined age thresholds differentiating M/M risk in patients randomized to placebo (Cox regression determining treatment effect by age). RESULTS: Three age groups (< 35, 35-64, ≥ 65 years) showed good M/M risk discrimination (c-statistic 0.69, SERAPHIN; 0.66, GRIPHON). M/M risk was higher in placebo patients < 35 versus 35-64 years (SERAPHIN: hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.10-2.72, p = 0.02; GRIPHON: HR 1.81, 95% CI 1.28-2.56, p < 0.001). M/M risk trended higher in patients ≥ 65 versus 35-64 years (SERAPHIN: HR 1.55, 95% CI 0.89-2.69, p = 0.12; GRIPHON (HR 1.08, 95% CI 0.75-1.55, p = 0.69). M/M risk was lower with macitentan/selexipag versus placebo: macitentan < 35 (HR 0.44, 95% CI 0.25-0.78; p = 0.005), 35-64 (HR 0.50, 95% CI 0.33-0.76; p < 0.001), ≥ 65 years (HR 0.69, 95% CI 0.30-1.58; p = 0.38); selexipag < 35 (HR 0.50, 95% CI 0.32-0.78; p = 0.002), 35-64 (HR 0.72, 95% CI 0.54-0.96; p = 0.03), ≥ 65 years (HR 0.55, 95% CI 0.33-0.91; p = 0.02). Adverse-event discontinuations were similar. CONCLUSIONS: The benefit (vs placebo) of macitentan/selexipag on reducing risk of M/M events was consistent across all ages, including the younger group where significant treatment effects were observed.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25008493
003      
CZ-PrNML
005      
20250422095831.0
007      
ta
008      
250408e20250116xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jhlto.2024.100197 $2 doi
035    __
$a (PubMed)40144855
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Channick, Richard $u David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
245    10
$a Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension / $c R. Channick, S. Medrek, M. Delcroix, S. Gaine, P. Jansa, I. Lang, V. McLaughlin, S. Mehta, T. Pulido, B. Sastry, R. Souza, A. Torbicki, C. Zhao, P. Strachan, P. Agron, J. Yen, O. Sitbon
520    9_
$a BACKGROUND: Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS: Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIPHON; NCT01106014) versus placebo (primary endpoint: time to morbidity/mortality [M/M]). This analysis defined age thresholds differentiating M/M risk in patients randomized to placebo (Cox regression determining treatment effect by age). RESULTS: Three age groups (< 35, 35-64, ≥ 65 years) showed good M/M risk discrimination (c-statistic 0.69, SERAPHIN; 0.66, GRIPHON). M/M risk was higher in placebo patients < 35 versus 35-64 years (SERAPHIN: hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.10-2.72, p = 0.02; GRIPHON: HR 1.81, 95% CI 1.28-2.56, p < 0.001). M/M risk trended higher in patients ≥ 65 versus 35-64 years (SERAPHIN: HR 1.55, 95% CI 0.89-2.69, p = 0.12; GRIPHON (HR 1.08, 95% CI 0.75-1.55, p = 0.69). M/M risk was lower with macitentan/selexipag versus placebo: macitentan < 35 (HR 0.44, 95% CI 0.25-0.78; p = 0.005), 35-64 (HR 0.50, 95% CI 0.33-0.76; p < 0.001), ≥ 65 years (HR 0.69, 95% CI 0.30-1.58; p = 0.38); selexipag < 35 (HR 0.50, 95% CI 0.32-0.78; p = 0.002), 35-64 (HR 0.72, 95% CI 0.54-0.96; p = 0.03), ≥ 65 years (HR 0.55, 95% CI 0.33-0.91; p = 0.02). Adverse-event discontinuations were similar. CONCLUSIONS: The benefit (vs placebo) of macitentan/selexipag on reducing risk of M/M events was consistent across all ages, including the younger group where significant treatment effects were observed.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Medrek, Sarah $u University of New Mexico, Albuquerque, NM
700    1_
$a Delcroix, Marion $u University Hospitals of Leuven, Leuven, Belgium
700    1_
$a Gaine, Sean $u National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland
700    1_
$a Jansa, Pavel $u Second Department of Internal Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Lang, Irene $u Department of Internal Medicine II, Cardiology and Center of Cardiovascular Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria
700    1_
$a McLaughlin, Vallerie $u University of Michigan, Ann Arbor, MI
700    1_
$a Mehta, Sanjay $u Respirology Division, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
700    1_
$a Pulido, Tomas $u Clinical Research Department, National Heart Institute, Mexico City, Mexico
700    1_
$a Sastry, Bhagavatula $u CARE Hospitals, Hyderabad, India
700    1_
$a Souza, Rogerio $u InCor, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
700    1_
$a Torbicki, Adam $u Centre of Postgraduate Medical Education, European Health Centre, ECZ-Otwock, Poland
700    1_
$a Zhao, Carol $u Actelion Pharmaceuticals US, Inc., (a Johnson & Johnson Company), Titusville, NJ
700    1_
$a Strachan, Paul $u Actelion Pharmaceuticals US, Inc., (a Johnson & Johnson Company), Titusville, NJ
700    1_
$a Agron, Peter $u Janssen Research and Development, LLC, Raritan, NJ
700    1_
$a Yen, Joseph $u Actelion Pharmaceuticals US, Inc., (a Johnson & Johnson Company), Titusville, NJ
700    1_
$a Sitbon, Olivier $u Université Paris-Saclay, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
773    0_
$w MED00216308 $t JHLT open $x 2950-1334 $g Roč. 7 (20250116), s. 100197
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40144855 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250408 $b ABA008
991    __
$a 20250422095833 $b ABA008
999    __
$a ok $b bmc $g 2306393 $s 1245568
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2025 $b 7 $c - $d 100197 $e 20250116 $i 2950-1334 $m JHLT open $n JHLT Open $x MED00216308
LZP    __
$a Pubmed-20250408

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...